Choi Geun Joo, Kim Hyun Min, Kang Hyun
Department of Anesthesiology and Pain Medicine, College of Medicine, Chung-Ang University, Seoul, Korea.
The institute of Evidence based clinical medicine, Chung-Ang University, Seoul, Korea.
J Lipid Atheroscler. 2020 Sep;9(3):435-448. doi: 10.12997/jla.2020.9.3.435. Epub 2020 Sep 21.
The aim of this study was to analyze the available knowledge about the potential association between dyslipidemia and the severity of coronavirus disease 2019 (COVID-19) as reported in previous published systematic reviews.
In this umbrella review (an overview of systematic reviews), we investigated the association between dyslipidemia and COVID-19 severity. A systematic search was performed of 4 main electronic databases (MEDLINE, Embase, Scopus, and the Cochrane Library databases) from inception until August 2020. We evaluated the methodological quality of the included studies using the A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2 tool and used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to assess the quality of evidence for the outcome. In addition, we evaluated the strengths and limitations of the evidence and the methodological quality of the available studies.
Out of 35 articles identified, 2 systematic reviews were included in the umbrella review. A total of 7,951 COVID-19-positive patients were included. According to the AMSTAR 2 criteria and GRADE system, the quality of the included studies was not high. A history of dyslipidemia is likely to be associated with the severity of COVID-19 infection, but the contrary is the case for cholesterol levels at hospitalization.
Although existing research on dyslipidemia and COVID-19 is limited, our findings suggest that dyslipidemia may play a role in the severity of COVID-19 infection. More adequately powered studies are needed.
PROSPERO Identifier: CRD42020205979.
本研究旨在分析既往发表的系统评价中报道的关于血脂异常与2019冠状病毒病（COVID-19）严重程度之间潜在关联的现有知识。
在本伞状评价（系统评价的概述）中，我们调查了血脂异常与COVID-19严重程度之间的关联。对4个主要电子数据库（MEDLINE、Embase、Scopus和Cochrane图书馆数据库）从创建至2020年8月进行了系统检索。我们使用评估系统评价的测量工具（AMSTAR）2工具评估纳入研究的方法学质量，并使用推荐分级、评估、制定和评价（GRADE）系统评估结局的证据质量。此外，我们评估了证据的优势和局限性以及现有研究的方法学质量。
在识别出的35篇文章中，2篇系统评价被纳入伞状评价。共纳入7951例COVID-19阳性患者。根据AMSTAR 2标准和GRADE系统，纳入研究的质量不高。血脂异常病史可能与COVID-19感染的严重程度相关，但住院时的胆固醇水平则相反。
尽管关于血脂异常和COVID-19的现有研究有限，但我们的研究结果表明血脂异常可能在COVID-19感染的严重程度中起作用。需要开展更有充分统计学效力的研究。
PROSPERO标识符：CRD42020205979。
